» Articles » PMID: 26333546

The Matrix Metalloproteinases 2 and 9 Initiate Uraemic Vascular Calcifications

Overview
Date 2015 Sep 4
PMID 26333546
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The matrix metalloproteinases (MMP) MMP-2 and MMP-9 are physiological regulators of vascular remodelling. Their dysregulation could contribute to vascular calcification. We examined the role of the MMP-2 and MMP-9 in uraemic vascular calcification in vivo and in vitro.

Methods: The impact of pharmacological MMP inhibition on the development of media calcifications was explored in an aggressive animal model of uraemic calcification. In addition, the selective effects of addition and inhibition, respectively, of MMP-2 and MMP-9 on calcium-/phosphate-induced calcifications were studied in a murine cell line of vascular smooth muscle cells (VSMCs).

Results: High-dose calcitriol treatment of uraemic rats given a high phosphate diet induced massive calcifications, apoptosis and increased gene expressions of MMP-2, MMP-9 and of osteogenic transcription factors and proteins in aortic VSMC. The MMP inhibitor doxycycline prevented the VSMC transdifferentiation to osteoblastic cells, suppressed transcription of mediators of matrix remodelling and almost completely blocked aortic calcifications while further increasing apoptosis. Similarly, specific inhibitors of either MMP-2 or -9, or of both gelatinases (Ro28-2653) and a selective knockdown of MMP-2/-9 mRNA expression blocked calcification of murine VSMC induced by calcification medium (CM). In contrast to MMP inhibition, recombinant MMP-2 or MMP-9 enhanced CM-induced calcifications and the secretion of gelatinases.

Conclusions: These data indicate that both gelatinases provide essential signals for phenotypic VSMC conversion, matrix remodelling and the initiation of vascular calcification. Their inhibition seems a promising strategy in the prevention of vascular calcifications.

Citing Articles

Calciprotein particle counts associate with vascular remodelling in chronic kidney disease.

Feenstra L, Reijrink M, Pasch A, Smith E, Visser L, Bulthuis M Cardiovasc Res. 2024; 120(15):1953-1966.

PMID: 39102822 PMC: 11629976. DOI: 10.1093/cvr/cvae164.


Matrix metalloproteinase-3 joins a growing list of proteases that regulate vascular calcification.

Giachelli C, Donato M, Scatena M Cardiovasc Res. 2024; 120(6):565-566.

PMID: 38630897 PMC: 11074787. DOI: 10.1093/cvr/cvae064.


Smooth muscle cell-specific matrix metalloproteinase 3 deletion reduces osteogenic transformation and medial artery calcification.

Xie Y, Lin T, Jin Y, Berezowitz A, Wang X, Lu J Cardiovasc Res. 2024; 120(6):658-670.

PMID: 38454645 PMC: 11074797. DOI: 10.1093/cvr/cvae035.


Role of matrix metalloproteinases in bone regeneration: Narrative review.

Khoswanto C J Oral Biol Craniofac Res. 2023; 13(5):539-543.

PMID: 37351418 PMC: 10282173. DOI: 10.1016/j.jobcr.2023.06.002.


Association Between Transforming Growth Factor-β1 Polymorphisms and Ischemic Stroke Susceptibility: A Meta-Analysis.

Peng X, Cheng F, Zhou L Clin Appl Thromb Hemost. 2023; 29:10760296231166666.

PMID: 36998191 PMC: 10068975. DOI: 10.1177/10760296231166666.